AUTHOR INDEX

Abraham G, 163, 167, 211
Addous A, 61
Ahmad R, 145
Ajzen A, 288
Andreoli SP, 137
Aramburo O, 207
Aramendi Sanchez T, 217
Arango JL, 207
Arbelaez M, 207
Arisz L, 19
Averbukh Z, 218
Ayiomamitis A, 211

Bailey S, 27
Barbosa D, 288
Bargman JM, 249
Bastani B, 27, 135
Beardsworth SF, 145
Beecroft ML, 125
Beelen RHJ, 199
Ben Abdallah T, 223
Ben Ayed H, 223
Ben Maiz H, 223
Bergstein JM, 137
Bergström J, 31
Black EB, 218
Blake P, 167
Boeschoten EW, 19
Bos HJ, 199
Brady HR, 163
Brenorowicz A, 249
Brownjohn AM, 203
Burgos D, 285

Camaño T, 273
Cardella CJ, 163
Carleton H, 62
Castelo A, 288
Chan MK, 287
Chandran PKG, 59
Chemleski B, 62
Churchill DN, 125
Cohn M, 218
Coles GA, 61
Copley JB, 195
Coulthard MG, 269
Cozma G, 56
Crucitti S, 58
Cruz C, 57
Curatola G, 58
Cuzzucri A, 58

Dadone C, 171
Damsgaard EM, 221
Davis M, 27
de Veld JC, 199
Dealler S, 167
DiRaimondo CR, 43
Diaz-Buxo JA, 218
Dibble JB, 203
Dobbie JW, 3, 241
Donnelly S, 187
Draibe S, 288

El Matri A, 223
El-Nahao AM, 61
Engels D, 27
Ethimiadou A, 55

Faber MD, 57
Fernandez A, 273
Fessia SL, 56, 169
Flynn CT, 59
Fowler M, 195
Francos von Hunefeld M, 217
Freer K, 27
Fries DS, 153
Frutos MA, 285

Gallar Ruiz P, 217
Garcia A, 207
Garel L, 265
Gibson J, 203
Gil NE, 207
Giltri C, 171
Goetz D, 155
Golper TA, 223
Gomez Roldan C, 217
Gragera F, 273
Grant AM, 203
Gratton C, 277
Grosfeld JL, 137
Guthrie A, 167

Haj M, 25
Hamburger RJ, 141
Hamilton RW, 129
Hauter F, 62
Heilesert AM, 218
Heimbürger O, 31, 253
Henao JE, 207
Hobson SM, 203
Horn T, 281

Ishizaki M, 221
Izatt S, 211

Jabłczynska A, 159
Jimenez del Cerro L, 60
Johnson CA, 191
Jones RG, 203

Kapsner CO, 235
Karim K, 145
Kechrid C, 223
Kehoe WA, 153
Khanna R, 119, 179
Koger DM, 195
Korniszewska J, 159
Kotsiou S, 55
Kowalewska K, 277
Krediet RT, 19
Kristal B, 25
Kurosawa K, 221

Levy M, 187
Lindblad AS, 129, 141
Lindholm B, 31, 253
Lipkin G, 167
Lopez de Novales E, 285

Mactier RA, 179
Maggiore Q, 58
Maltezos E, 55
Manuel A, 125
Marzluff C, 155
Mathews RE, 211
McCarley P, 43
Mejia G, 207
Modai D, 218
Moore H, 179
Motz D, 155

Nielsen D, 62
Nolph KD, 129, 141, 179
Novak JW, 129, 141

O'Brien M, 191
O'Kane M, 203
O'Regan, 265
Oe LP, 199
Olivares Martin J, 60
Oreopoulos DG, 1, 113, 125, 163, 211, 233, 249

Palop L, 273
Pasadakis P, 55
Paton T, 125
Patriquin H, 265
Plaza C, 273
Prichard S, 187
Prowant BF, 11
Pustorino D, 58

Ramos B, 285
Rapoport M, 218
Read D, 27
Redaelli B, 171
Rivera Hernandez F, 60
Roberts DE, 61
Rodela H, 249
Rodgers DJ, 195
Rodriguez-Perez JC, 273
Roszkowska-Blaim M, 159
Ruiz A, 285
Ryan S, 56, 169

Sanchez J, 207
Santiago Guervos C, 60
Sato I, 288
Savin E, 211
Scatizzi A, 57
Schreiber MJ, 7
Sesso R, 288
Sharp J, 269
Shasha SM, 25
Shashi Kant K, 155
Sherman RA, 27
Shishido Y, 221
Siclari F, 58
Sieniawska M, 159
Singer J, 125
Smith BJ, 195
Smith EKM, 125
Sombolos K, 249
Spyker DA, 135
Stablein DM, 141
Steiner RW, 238
Stone WJ, 43
Strippoli P, 57
Suzuki K, 221

Takahashi H, 221
Taylor DW, 125
Terry E, 145
Thodis E, 55
Tompkins L, 203
Tranæus A, 31, 253
Turney JH, 203
Twardowski ZJ, 15, 59, 119, 179, 223
Tyroler J, 218
Tzamaloukas AH, 235

van der Meulen J, 199
Vargemezis V, 55
Vas SI, 125, 211, 229
Vaudry WL, 277
Vega N, 273
Vigano F, 171
Vigil Medina A, 217
Vlaanderen K, 199

Walker S, 125
Weber JN, 153
Wegmann F, 281
Wenman WM, 277
West KW, 137
Westervelt FB Jr., 27, 135
Wiedenhoeft FA, 191
Wierzbowska-Lange, 159
Williams JD, 61
Wing T, 223
Wu G, 125

Yazbeck S, 265
Young GA, 203

Zimmerman SW, 191
Zoccali C, 58
Zuyderhoudt FMJ, 19

SUBJECT INDEX

Acinetobacter calcoaceticus, 285
Adequate dialysis, 31
Amyloidosis, 43
Antibiotics, 277
Antimicrobal susceptibility, 277
Aspergillus fumigatus, 281
Automated dialysis, 269

Beta-2 microglobulin, 43
Bowel perforation, 163

Cardiovascular, 203
Catheter complications, 129
Catheter cuff, 129
Catheter survival, 129
Catheter, 195, 265, 281
Chronic renal failure, 31
Clindamycin, 153
Colonization, 281
Compatibility, 153
Complications, 207
Continuous ambulatory peritoneal dialysis (CAPD), 19, 25, 27, 31, 43, 125, 129, 135, 137, 141, 145, 153, 159
Continuous ambulatory peritoneal dialysis (CAPD) complications, 163
Continuous cyclic peritoneal dialysis (CCPD), 129, 141, 199
Cotrimoxazole, 125
Cyst, 273
Cystic disease, 273

Daptomycin, 277
Diabetes, 145
Dialysis-associated amyloidosis, 43
Dietary fish oil, 203

End-stage renal failure, 159
Erythropoietin, 249
Exit site, 195
Exit-site infection, 191, 211

Gentamycin, 153
Gore-Tex™, 129

Heat-sealing device, 269
Hypercalcemia, 187
Hyperlipidemia, 203
Hypertension, 141

Immunosuppressive therapy, 163
India ink, 179
Insulin, 145
Intraperitoneal (i.p) antibiotic therapy, 155
Intraperitoneal, 145

Laceration of intestine, 25
Lipids, 19
Long-term follow-up, 207
Lymphatics, 179

Macrophage function, 155
Manual dialysis, 269

Nonpurulent, 211

Opsonins, 155
Outflow obstruction, 265
Oxacillin, 277

Pancreatitis, 187
Pathogenesis, 253
Peritoneal catheter, 129
Peritoneal dialysis, 27, 43, 135, 153
Peritoneal macrophages, 199
Peritoneal transport, 249
Peritonitis, 27, 31, 125, 135, 163, 191, 199, 207, 211, 253, 269, 281, 285
Phagocytic activity, 155
Phagocytosis, 199
Phosphatidylcholine, 179
Postoperative infections, 195
Prevention, 195
Purulent, 211

Relapsing peritonitis, 155
Renal transplantation, 163
Risk factors, 253

Solute clearances, 179
Staphylococcus aureus, 191, 277
Streptokinase, 137
Survival, 31, 207

Tenckhoff catheter failure, 137
Tenckhoff catheter, 129, 281
Three daily exchanges, 207
Toronto-Western, 129
Triglycerides, 203

Ultrafiltration, 179
Ultrasonography, 273

Vancomycin, 27, 135, 277

Weight gain, 19
Whiplash technique, 265